NCT06970847 - 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer | Biotech Hunter

Enrollment

220

Participants

Timeline

Start Date

May 16, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Prostate CancerProstate Cancer Patients With Detectable PSA Following ProstatectomyProstate Cancer RecurrentProstate Cancer Patients Who Have Brachytherapy Seed ImplantProstate Cancer Patients Treated by RadiotherapyCryotherapy

Interventions

DRUG

64Cu-SAR-bisPSMA

All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA

Trial Locations (3)

33165

RECRUITING

Biogenix Molecular, Miami

68130

RECRUITING

XCancer, Omaha

78240

RECRUITING

The Urology Place, San Antonio